Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry.
Ge Z, Baber U, Claessen BE, Farhan S, Chandrasekhar J, Li SX, Sartori S, Kini AS, Rao SV, Weiss S, Henry TD, Vogel B, Sorrentino S, Faggioni M, Kapadia S, Muhlestein B, Strauss C, Toma C, DeFranco A, Effron MB, Keller S, Baker BA, Pocock S, Dangas G, Mehran R. Ge Z, et al. Among authors: effron mb. Catheter Cardiovasc Interv. 2019 Feb 15;93(3):E112-E119. doi: 10.1002/ccd.27860. Epub 2018 Oct 23. Catheter Cardiovasc Interv. 2019. PMID: 30351514
Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: results of ReoMI pilot study.
Makkar R, Goff B, Eigler N, Sebastian M, Fischell T, Barr L, D'Haem C, Shah PK, Effron MB, Litvack F. Makkar R, et al. Among authors: effron mb. Catheter Cardiovasc Interv. 1999 Dec;48(4):430-4. doi: 10.1002/(sici)1522-726x(199912)48:4<430::aid-ccd20>3.0.co;2-g. Catheter Cardiovasc Interv. 1999. PMID: 10559827
Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW; CADILLAC Investigators. Tcheng JE, et al. Among authors: effron mb. Circulation. 2003 Sep 16;108(11):1316-23. doi: 10.1161/01.CIR.0000087601.45803.86. Epub 2003 Aug 25. Circulation. 2003. PMID: 12939213 Clinical Trial.
Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial).
Kandzari DE, Tcheng JE, Cohen DJ, Bakhai A, Grines CL, Cox DA, Effron M, Stuckey T, Griffin JJ, Turco M, Carroll JD, Fahy M, Mehran R, Stone GW; CADILLAC Investigators. Kandzari DE, et al. Am J Cardiol. 2003 Oct 1;92(7):779-84. doi: 10.1016/s0002-9149(03)00882-8. Am J Cardiol. 2003. PMID: 14516875 Clinical Trial.
TransRadial Education and Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research Consortium.
Hess CN, Rao SV, Kong DF, Miller JM, Anstrom KJ, Bertrand OF, Collet JP, Effron MB, Eloff BC, Fadiran EO, Farb A, Gilchrist IC, Holmes DR, Jacobs AK, Kaul P, Newby LK, Rutledge DR, Tavris DR, Tsai TT, White RM, Peterson ED, Krucoff MW. Hess CN, et al. Among authors: effron mb. Am Heart J. 2013 Mar;165(3):344-53.e1. doi: 10.1016/j.ahj.2012.09.008. Am Heart J. 2013. PMID: 23453103 Free PMC article.
Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention.
Wang TY, McCoy L, Henry TD, Effron MB, Messenger JC, Cohen DJ, Mark DB, Stone GW, Zettler M, Singh M, Fonarow GC, Peterson ED; TRANSLATE-ACS Study Investigators. Wang TY, et al. Among authors: effron mb. J Am Coll Cardiol. 2014 Apr 29;63(16):1700-2. doi: 10.1016/j.jacc.2013.12.012. Epub 2014 Jan 30. J Am Coll Cardiol. 2014. PMID: 24486275 Free article. No abstract available.
113 results